Mead Alice
GW Pharmaceuticals, Inc., 5800 Armada Dr., Suite 210, Carlsbad, CA 92008, United States.
Epilepsy Behav. 2017 May;70(Pt B):288-291. doi: 10.1016/j.yebeh.2016.11.021. Epub 2017 Feb 4.
In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50% of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use. Many of these artisanal products are sold in dispensaries or over the internet. However, none of these products has been approved by the Food and Drug Administration (FDA). Understanding how federal laws apply to clinical research and practice can be challenging, and the complexity of these laws has resulted in particular confusion regarding the legal status of CBD. This paper provides an up-to-date overview (as of August 2016) of the legal aspects of cannabis and cannabidiol, including cultivation, manufacture, distribution, and use for medical purposes. This article is part of a Special Issue title, Cannabinoids and Epilepsy.
在美国,联邦和州关于大麻及大麻素医疗用途的法律相互冲突,这导致患者、护理人员及医疗服务提供者感到困惑。目前,大麻在50%的州用于医疗目的是合法的,另有17个州允许使用大麻二酚(CBD)含量高、四氢大麻酚(THC)含量低的产品用于医疗。许多此类手工制作的产品在药房或通过互联网销售。然而,这些产品均未获得美国食品药品监督管理局(FDA)的批准。理解联邦法律如何适用于临床研究和实践颇具挑战性,这些法律的复杂性尤其导致了人们对CBD法律地位的困惑。本文提供了一份(截至2016年8月)关于大麻和大麻二酚法律方面的最新概述,包括种植、制造、分销及医疗用途。本文是《大麻素与癫痫》特刊的一部分。